BEGACESTAT (C005B-432679)

Catalog No.: C005B-432679
Mfr. No.: PZ0187-5MG
Mfr. Name: Sigma-Aldrich
Qty/UOM: 5
UOM: MG

Price: $319.17

List Price: $354.63

Biochem/physiol Actions Begacestat (GSI-953) is a selective γ:-secretase inhibitor that selectively inhibits cleavage of APP over Notch. Other Notes This compound was developed by Pfizer for Neuroscience research .

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Biochem/physiol Actions

Begacestat (GSI-953) is a selective γ-secretase inhibitor that selectively inhibits cleavage of APP over Notch.

Other Notes

This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Pfizer Inc.

Pfizer is a registered trademark of Pfizer, Inc.

UPC:: 51182701
Condition:: New
Availability:: 3-5 Days
Weight:: 1.00 Ounces
HazmatClass:: No
MPN:: PZ0187-5MG
CAS:: 769169-27-9

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."